COVID-19 lessons for medical practice. Methylene blue is a time-tested innovation
Keywords:COVID-19, methylthioninium chloride, methylene blue, Pembina Blue®, prevention of pneumonia, urinary tract antiseptic
Significance of methylene blue (MB) in therapy of methemoglobinemia, malaria and urinary tract infections (UTI) is well known. The antimicrobial, anti-inflammatory, and antioxidant effect of MB has been demonstrated in different in vitro and in vivo studies. Necessity to find the remedy against COVID-19 attracted the interest of investigators and general practitioners to MB worldwide. The review includes various experiences of MB use, in particular in the patients treated with MB during the COVID-19 epidemic with a preventive effect, as well as own experience on this topic. MB is widely used as a dye in a variety of biological sciences applications — diagnostic procedures and the treatment of multiple disorders, including cyanide, and carbon monoxide poisoning, and is considered to be nontoxic. The beneficial effects of MB in the management of patients with multiple small renal calculi, especially with infected stones, and prevention of new stone formation were presented in a 5-year study. Moreover, due to MB antifungal potential and antimicrobial effect, it reduces symptoms of UTI, improves quality of life and could prevent the recurrence of disease. The patented complex of MB with sage leaf extract and American cranberry fruit extract (Pembina Blue®) demonstrated significant reduction of pain and spasm in cystitis patients. Given the limited number of available UTI therapies with concomitant increase in drug resistance, the demand for the search of new safe and effective UTI treatments are inevitable. Considering the fact that MB is FDA-approved compound that is already used for various therapeutic options, and also owing to the distinct antioxidant, antifungal, antibacterial and anti-inflammatory mechanisms presented in this review, MB could be considered as a promising drug for future.
Ministry of Нealth of Ukraine. Order on December 31, 2020 № 3094. On Amendments to the Protocol on Providing Medical Care for the Treatment of Coronavirus Disease COVID-19. Available from: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-31122020--3094-pro-vnesennja-zmin-do-protokolu--nadannja-medichnoi-dopomogi-dlja-likuvannja--koronavirusnoi-hvorobi-covid-19. Accessed: December 31, 2020. (in Ukrainian).
Alamdari DH, Moghaddam AB, Amini S, et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol. 2020 Oct 15;885:173494. doi:10.1016/j.ejphar.2020.173494.
Henry M, Summa M, Patrick L, Schwartz L. A cohort of cancer patients with no reported cases of SARS-CoV-2 infection: the possible preventive role of Methylene Blue. Substantia. 2020;4(Suppl 1):888. doi:10.13128. 2020.
Fall B, Camara C, Fall M, et al. Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season. Malar J. 2015 Feb 6;14:60. doi:10.1186/s12936-015-0589-3.
Nedu ME, Tertis M, Cristea C, Georgescu AV. Comparative study regarding the properties of methylene blue and proflavine and their optimal concentrations for in vitro and in vivo applications. Diagnostics (Basel). 2020 Apr 15;10(4):223. doi:10.3390/diagnostics10040223.
Pal R, Ansari MA, Saibabu V, Das S, Fatima Z, Hameed S. Nonphotodynamic Roles of Methylene Blue: Display of Distinct Antimycobacterial and Anticandidal Mode of Actions. J Pathog. 2018 Jan 31;2018:3759704. doi:10.1155/2018/3759704.
Gendrot M, Madamet M, Mosnier J, et al. Baseline and multinormal distribution of ex vivo susceptibilities of Plasmodium falciparum to methylene blue in Africa, 2013-18. J Antimicrob Chemother. 2020 Aug 1;75(8):2141-2148. doi:10.1093/jac/dkaa174.
Geller M, Gama CRB, Guimarães OR, et al. Recurrent urinary tract infections: Evaluation of the prophylactic efficacy of urinary antiseptics methenamine and methylthioninium chloride. Rev Bras Med. 2008 Nov;65:367-371.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.